Given our optimal dose/minimal effective dose is yet to be authorised.
Given the drug is yet to be classified as a “pain and function” or “Dmoad” drug
Given ambiguity around phase 3 trial metrics
Given TGA may or may not authorise our early application
Given cautious global bio pharma market environment
Given our supplier may also hold some decision making power on partnerships
Given our dire financial situation
……. maybe, just maybe our “deal” potential is held up until some of these dominos fall one way or another.
I’m not for a second saying I’m right here, or that others are wrong. I think some of the slides from last Fridays slide deck are encouraging, though.
Given our optimal dose/minimal effective dose is yet to be...
-
- There are more pages in this discussion • 144 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.0¢ |
Change
0.010(4.55%) |
Mkt cap ! $80.45M | |||
| Open | High | Low | Value | Volume |
| 22.8¢ | 23.3¢ | 22.5¢ | $46.92K | 203.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 337 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 138166 | 5 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |